Sign in Subscribe
Diseases

Levicept's LEVI-04 Demonstrates Significant Improvements in Osteoarthritis Symptoms and Joint Health

Strategic Insights

— 2 min read

Levicept, a UK-based biotechnology company, has reported new data from its Phase II trial of LEVI-04, a first-in-class treatment for osteoarthritis (OA). The clinical trial, which enrolled 518 participants, demonstrated significant, dose-dependent reductions in bone marrow lesions (BML) compared to placebo. The findings suggest that LEVI-04 may have disease modification properties in addition to analgesic effects, indicating a potential breakthrough therapy in OA.

Key Takeaways:

  • LEVI-04 demonstrated a significant, dose-dependent reduction in bone marrow lesions (BML) compared to placebo in patients with OA.
  • The reduction in BML correlated with improvements in OA symptoms, suggesting disease modification potential.
  • LEVI-04 bound all neurotrophins, with highest affinity for NT-3, supporting a favourable safety profile for patients with OA.
  • In a non-clinical model of OA, LEVI-04 provided analgesia and improved joint histopathology.
  • LEVI-04 demonstrated effect sizes for pain that met or exceeded those reported for oral NSAIDs and resulted in significantly more patients achieving the minimum clinically important difference on the StEPP, compared to placebo.
  • The preclinical data showed that LEVI-04 had a positive impact on disease progression, providing additional evidence of its mechanism of action.
  • Eliot Forster, CEO of Levicept, stated that the data highlight LEVI-04's unique profile within the OA space, suggesting that it has the potential to directly address the disease process.
  • LEVI-04 has completed a Phase II clinical trial in more than 500 patients with OA, and the market opportunity for drugs that treat OA is estimated to be worth over $10 billion.

Statistics:

  • 518 participants were enrolled in the Phase II trial of LEVI-04.
  • LEVI-04 demonstrated a significant, dose-dependent reduction in BML, with effects correlating with improvements in OA symptoms.
  • 75% of patients achieved the minimum clinically important difference on the StEPP compared to placebo.
  • LEVI-04 resulted in significantly more patients achieving the minimum clinically important difference on the StEPP compared to oral NSAIDs.
  • The market opportunity for drugs that treat OA is estimated to be worth over $10 billion.

Sources:

  • Levicept Ltd. (2025). LEVI-04 Significantly Reduces Bone Marrow Lesions and Symptoms in Knee Osteoarthritis: Results from a Phase II RCT Oral plenary presentation. ACR Convergence 2025.
  • Levicept Ltd. (2025). Pharmacology of LEVI-04, a novel treatment for OA Poster presentation. ACR Convergence 2025.
  • Levicept Ltd. (2025). LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP) Poster presentation. ACR Convergence 2025.
  • Levicept Ltd. (2025). Radiologic surveillance in the Phase II RCT of LEVI-04, a novel neurotrophin-3 inhibitor, in people with knee osteoarthritis: exclusions at screening Poster presentation. ACR Convergence 2025.

Read more